Seminal plasma LDH-X in testosterone rebound therapy

Area of Science:

• Reproductive Endocrinology
• Clinical Biochemistry

Background:

• Oligozoospermia, characterized by low sperm counts, presents a significant challenge in male fertility.
• Testosterone therapy is a potential treatment for certain types of male infertility.
• Identifying reliable biomarkers for predicting treatment response is crucial for effective management.

Purpose of the Study:

• To investigate the changes in seminal plasma lactate dehydrogenase-X (LDH-X) isoenzyme in oligozoospermic patients undergoing testosterone therapy.
• To assess the potential of seminal plasma LDH-X as an early predictor of sperm count elevation and a marker for patient selection in testosterone treatment.

Main Methods:

• Analysis of seminal plasma LDH-X isoenzyme levels in 27 oligozoospermic patients.
• Monitoring changes in LDH-X isoenzyme in relation to sperm count following testosterone administration.
• Correlation of initial LDH-X levels with treatment response, particularly in severe oligozoospermia cases.

Main Results:

• An increase in seminal plasma LDH-X isoenzyme was observed prior to the elevation of sperm count in patients treated with testosterone.
• Patients with severe oligozoospermia (<0.1 x 10^6 spermatozoa/ml) showed a higher response rate when they had a high initial relative percentage of seminal plasma LDH-X.
• The study identified a potential correlation between baseline seminal plasma LDH-X levels and the likelihood of responding to testosterone therapy.

Conclusions:

• Seminal plasma LDH-X isoenzyme may serve as an early predictive biomarker for sperm count improvement during testosterone therapy.
• Measuring seminal plasma LDH-X could aid in selecting oligozoospermic patients who are most likely to benefit from testosterone treatment.
• This biomarker may help optimize the timing for conception attempts in treated patients.